MyoKardia, Inc.
(NASDAQ : MYOK)

( )
MYOK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc -3.06%74.046.7%$159.00m
VRXValeant Pharmaceuticals International, Inc. 15.93%22.5614.1%$132.75m
CTLTCatalent, Inc. 2.64%92.002.1%$96.26m
BHCBausch Health Cos., Inc. 15.93%22.560.0%$74.92m
JAZZJazz Pharmaceuticals Plc 1.85%124.502.4%$69.80m
TNXPTonix Pharmaceuticals Holding Corp. 0.80%1.260.5%$63.00m
PCRXPacira Biosciences, Inc. 1.48%56.1010.3%$46.06m
ARGXargenx SE 0.75%233.180.0%$43.85m
PRGOPerrigo Co. Plc -0.92%51.506.8%$43.25m
ICLRICON plc 1.42%189.744.1%$42.65m
ICPTIntercept Pharmaceuticals, Inc. -0.08%48.0016.8%$39.28m
GWPHGW Pharmaceuticals Plc 0.79%136.006.2%$39.08m
UTHRUnited Therapeutics Corp. -0.89%113.0714.1%$38.84m
MYOKMyoKardia, Inc. 2.01%99.971.8%$37.91m
AMRNAmarin Corp. Plc 0.44%6.891.5%$37.48m

Company Profile

MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.